Q-omics provides the consensus-scored LMO3 profile across patient tissues and cancer cell-line models. LMO3 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, LMO3 is differentially expressed in 16, with the highest sampling consensus in BLCA. Additionally, LMO3 RNA expression shows 20,100 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UCEC, BLCA, and LSCC as cancer lineages where LMO3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LMO3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LMO3 survival associations across molecular data types. LMO3 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LMO3 RNA expression–survival associations across cancer types. High LMO3 expression shows unfavorable associations in UCEC, LUSC, LIHC and HNSC, but favorable associations in SCLC and LUAD. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for LMO3 RNA expression.
This table summarizes LMO3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for LMO3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LMO3 shows lower tumor expression in BLCA, KICH, KIRC, KIRP, COAD and LUSC. The BLCA box plot shows higher LMO3 RNA expression in normal versus tumor tissue (log2 FC = −3.861, t-test p < 0.001).
This table shows molecular features associated with LMO3 in patient tissues and cancer cell lines. In patient samples, LMO3 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, LMO3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BONE.
